SS
TCRX icon

SBI Securities’s TScan Therapeutics TCRX Stock Holding History

SBI Securities’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$396 Hold
392
– – ﹤0.01% 2977
2025
Q4 		$392 Buy
392
+180
+85% +$261 ﹤0.01% 2964
2025
Q3 		$386 Buy
212
+1
+0.5% +$2 ﹤0.01% 3074
2025
Q2 		$306 Hold
211
– – ﹤0.01% 3170
2025
Q1 		$291 Buy
211
+150
+246% +$324 ﹤0.01% 3081
2024
Q4 		$185 Buy
+61
New +$276 ﹤0.01% 3270

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

SBI Securities's TCRX Position: Q1 2026 in Review

SBI Securities held its TScan Therapeutics (TCRX) position steady in Q1 2026 at 392 shares worth $396. The position accounts for ﹤0.01% of the portfolio, ranked #2977.

SBI Securities first reported a position in TCRX in Q4 2024 and has held it in 6 quarters since. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • SBI Securities held 392 shares of TScan Therapeutics worth $396 as of Q1 2026.
  • SBI Securities left its TScan Therapeutics share count unchanged in Q1 2026.
  • TScan Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q1 2026, its #2977 holding.
  • SBI Securities first reported a position in TScan Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.